These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 29370185)

  • 1. Adjuvanting influenza hemagglutinin vaccine with a human pulmonary surfactant-mimicking synthetic compound SF-10 induces local and systemic cell-mediated immunity in mice.
    Kim H; Kimoto T; Sakai S; Takahashi E; Kido H
    PLoS One; 2018; 13(1):e0191133. PubMed ID: 29370185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral vaccination with influenza hemagglutinin combined with human pulmonary surfactant-mimicking synthetic adjuvant SF-10 induces efficient local and systemic immunity compared with nasal and subcutaneous vaccination and provides protective immunity in mice.
    Kimoto T; Kim H; Sakai S; Takahashi E; Kido H
    Vaccine; 2019 Jan; 37(4):612-622. PubMed ID: 30553569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of systemic and mucosal immunity and maintenance of its memory against influenza A virus by nasal vaccination using a new mucosal adjuvant SF-10 derived from pulmonary surfactant in young cynomolgus monkeys.
    Mizuno D; Kimoto T; Sakai S; Takahashi E; Kim H; Kido H
    Vaccine; 2016 Apr; 34(16):1881-8. PubMed ID: 26954466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal influenza vaccination using a new synthetic mucosal adjuvant SF-10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses.
    Kimoto T; Mizuno D; Takei T; Kunimi T; Ono S; Sakai S; Kido H
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1218-26. PubMed ID: 23710832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
    Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen.
    Mizuno D; Ide-Kurihara M; Ichinomiya T; Kubo I; Kido H
    J Immunol; 2006 Jan; 176(2):1122-30. PubMed ID: 16394001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a safe and effective novel synthetic mucosal adjuvant SF-10 derived from physiological metabolic pathways and function of human pulmonary surfactant.
    Kimoto T
    Vaccine; 2022 Jan; 40(3):544-553. PubMed ID: 34887132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen-specific CD8(+) T cells persist in the upper respiratory tract following influenza virus infection.
    Wiley JA; Hogan RJ; Woodland DL; Harmsen AG
    J Immunol; 2001 Sep; 167(6):3293-9. PubMed ID: 11544317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs.
    Nishino M; Mizuno D; Kimoto T; Shinahara W; Fukuta A; Takei T; Sumida K; Kitamura S; Shiota H; Kido H
    Vaccine; 2009 Sep; 27(41):5620-7. PubMed ID: 19647064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective Respiratory CD8 T-Cell Immunity to Influenza Virus Induced by Intranasal Carbomer-Lecithin-Adjuvanted Non-replicating Vaccines.
    Gasper DJ; Neldner B; Plisch EH; Rustom H; Carrow E; Imai H; Kawaoka Y; Suresh M
    PLoS Pathog; 2016 Dec; 12(12):e1006064. PubMed ID: 27997610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice.
    Ninomiya A; Ogasawara K; Kajino K; Takada A; Kida H
    Vaccine; 2002 Aug; 20(25-26):3123-9. PubMed ID: 12163263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK; Tomar P; Sharma V; Dixit VK
    Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
    Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
    Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal Vaccination With Recombinant
    Wei J; Hegde VL; Yanamandra AV; O'Hara MP; Keegan B; Jones KM; Strych U; Bottazzi ME; Zhan B; Sastry KJ; Hotez PJ
    Front Immunol; 2022; 13():800295. PubMed ID: 35197976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surfactant protein C is an essential constituent for mucosal adjuvanticity of Surfacten, acting as an antigen delivery vehicle and inducing both local and systemic immunity.
    Mizuno D; Kimoto T; Takei T; Fukuta A; Shinahara W; Takahashi E; Yano M; Kido H
    Vaccine; 2011 Jul; 29(33):5368-78. PubMed ID: 21669246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
    Keijzer C; Haijema BJ; Meijerhof T; Voorn P; de Haan A; Leenhouts K; van Roosmalen ML; van Eden W; Broere F
    Vaccine; 2014 May; 32(24):2904-10. PubMed ID: 24598720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.
    Wang D; Christopher ME; Nagata LP; Zabielski MA; Li H; Wong JP; Samuel J
    J Clin Virol; 2004 Dec; 31 Suppl 1():S99-106. PubMed ID: 15567101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of functional influenza virus-specific CD8(+) T cell memory pools after intramuscular immunization.
    Wang Z; Chua BY; Ramos JV; Parra SM; Fairmaid E; Brown LE; Jackson DC; Kedzierska K
    Vaccine; 2015 Sep; 33(39):5148-54. PubMed ID: 26277069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.